C
Serum creatinine
Renal & ElectrolyteLab test / biomarkerriskpartially modifiable
24
evidence score
Also known as: creatinine
PREVENT status
Not a PREVENT input variable.
Causal support
trial evidence
Score components
lit volume: 15.4meta-analyses: 0trials: 8.4genetic: 0MR bonus:
References (34)
0 meta-analyses / systematic reviews- Association of intra-individual differences in estimated GFR by creatinine versus cystatin C with incident cardiovascular disease. — Nutrition, metabolism, and cardiovascular diseases : NMCD 2025 · PMID 40274428
- Association Between the Serum Creatinine to Cystatin C Ratio and Cardiovascular Disease in Middle-Aged and Older Adults in China: A Nationwide Cohort Study. — Journal of the American Heart Association 2025 · PMID 40281656
- Association of urinary dipeptidyl peptidase 4 activity with clinical outcomes in people with chronic kidney disease. — Scientific reports 2025 · PMID 40604004
- Incident cardiovascular diseases and changes in the ratio of serum creatinine to cystatin C: the sarcopenia index. — Nutrition, metabolism, and cardiovascular diseases : NMCD 2025 · PMID 41241623
- The Prevalence and Factors Associated with Coronary Heart Disease in Patients with Gout. — Doklady. Biochemistry and biophysics 2024 · PMID 39002009
- Cystatin C and sarcopenia index are associated with cardiovascular and all-cause death among adults in the United States. — BMC public health 2024 · PMID 39044229
- Different associations of atherogenic index of plasma, triglyceride glucose index, and hemoglobin A1C levels with the risk of coronary artery calcification progression according to established diabetes. — Cardiovascular diabetology 2024 · PMID 39563338
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients — New England Journal of Medicine 2023 · PMID 36876740
- Central and brachial pulse pressure predicts cardiovascular and renal events in treated hypertensive patients. — Blood pressure 2022 · PMID 35438015
- Association of Cystatin C Kidney Function Measures With Long-term Deficit-Accumulation Frailty Trajectories and Physical Function Decline. — JAMA network open 2022 · PMID 36178684
- Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study. — Irish journal of medical science 2021 · PMID 34476725
- Pulse Wave Velocity, Central Haemodynamic Parameters, and Markers of Kidney Function in Children. — Kidney & blood pressure research 2021 · PMID 34657030
- Differential risk factor profile of diabetes and atherosclerosis in rural, sub-urban and urban regions of South India: The KMCH-Non-communicable disease studies. — Diabetic medicine : a journal of the British Diabetic Association 2020 · PMID 33236348
- Cardiovascular Risk Prediction in CKD. — Seminars in nephrology 2018 · PMID 29753398
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. — The New England journal of medicine 2016 · PMID 27299675
- Adiposity markers and risk of coronary heart disease in patients with type 2 diabetes mellitus. — Nutrition journal 2014 · PMID 25539716
- Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors — Arteriosclerosis Thrombosis and Vascular Biology 2013 · PMID 23887638
- [The importance of NGAL and cystatin C biomarkers in cardiovascular diseases]. — Vnitrni lekarstvi 2012 · PMID 22559802
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management — European Heart Journal 2011 · PMID 21531743
- Should eGFR and Albuminuria Be Added to the Framingham Risk Score Chronic Kidney Disease and Cardiovascular Disease Risk Prediction — Nephron Clinical Practice 2011 · PMID 21811078
- Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. — Stroke 2010 · PMID 20150544
- Cystatin C and cardiovascular risk. — Clinical chemistry 2009 · PMID 19713275
- Uric Acid and Incident Kidney Disease in the Community — Journal of the American Society of Nephrology 2008 · PMID 18337481
- Decreased Glomerular Filtration Rate Is a Risk Factor for Hemorrhagic But Not for Ischemic Stroke — Stroke 2007 · PMID 17962600
- Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. — Annals of internal medicine 2006 · PMID 16908914
- Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) — BMJ 2006 · PMID 17032691
- Traditional and Nontraditional Risk Factors Predict Coronary Heart Disease in Chronic Kidney Disease — Journal of the American Society of Nephrology 2005 · PMID 15625072
- Chronic kidney disease as cause of cardiovascular morbidity and mortality — Nephrology Dialysis Transplantation 2005 · PMID 15814534
- Cystatin C and the risk of death and cardiovascular events among elderly persons. — The New England journal of medicine 2005 · PMID 15901858
- Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. — Current medical research and opinion 2004 · PMID 14741073
- Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality — Journal of the American Society of Nephrology 2004 · PMID 15100371
- Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction — New England Journal of Medicine 2004 · PMID 15385655
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization — New England Journal of Medicine 2004 · PMID 15385656
- Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction — Circulation 2004 · PMID 15569840
Clinical trials (6)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT07588256 | New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAM | RECRUITING | INTERVENTIONAL | Interactive digital modules, Antihypertensive Medication Management |
| NCT06910098 | Assessment of Impact of Rosuvastatin Doses on Low Density Lipoprotein Levels, Creatinine Phosphokinase Levels and Aspartate Aminotransferase Levels: A Randomized Controlled Trail | COMPLETED | INTERVENTIONAL | Rosuvastatin, Rosuvastatin, Rosuvastatin |
| NCT05874141 | Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, Egypt | COMPLETED | INTERVENTIONAL | HBA1C, Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides, Urine analysis and urinary albumin-to-creatinine ratio |
| NCT03226899 | A Phase 4, Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance (eCrCl) 30 to <60 mL/Min Who Have Not Achieved Target Serum Uric Acid Levels (sUA) on an XOI Alone | TERMINATED | INTERVENTIONAL | Lesinurad, XOI, Placebo |
| NCT05214872 | Assessment of the Impact of Selected Factors on the Cardiovascular System in Patients With Different Chronic Kidney Disease Stages | COMPLETED | OBSERVATIONAL | laboratory parameters - complete blood count, body mass index (BMI) [kg/m^2] calculation, selected parameters of oxidative stress (1) |
| NCT02226055 | An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka | COMPLETED | OBSERVATIONAL | Arterial Stiffness Assessment |
Genetic associations (0)
None linked.